Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cinacalcet
Drug ID BADD_D02434
Description Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar？ in North America and Australia and as Mimpara？ in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
Indications and Usage For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.
Marketing Status Not Available
ATC Code H05BX01
DrugBank ID DB01012
KEGG ID D03504
MeSH ID D000069449
PubChem ID 156419
TTD Drug ID D03YGR
NDC Product Code 51407-297; 43598-368; 42291-461; 72865-152; 50268-153; 47335-379; 42291-459; 65162-213; 16714-079; 31722-104; 63629-8763; 42291-460; 64380-885; 67877-505; 68180-227; 68180-228; 72865-151; 65162-155; 16729-440; 63629-8765; 43598-367; 31722-103; 16714-080; 31722-105; 16729-441; 69097-410; 60687-525; 69097-412; 16714-078; 65862-831; 72865-150; 65862-833; 47335-380; 69097-411; 47335-600; 76282-676; 51407-296; 42543-961; 0904-7067; 65862-832; 76282-674; 64380-883; 64380-884; 42543-962; 43598-369; 51407-295; 67877-503; 67877-504; 42543-963; 68180-226; 76282-675; 65162-157; 63629-8764; 16729-442
Synonyms Cinacalcet | Cinacalcet Hydrochloride | Alpha-methyl-N-(3-(3-(trifluoromethyl)phenyl)propyl)-1-naphthalenemethanamine, (alphaR)-hydrochloride | Sensipar | AMG 073 | KRN 1493 | AMG073
Chemical Information
Molecular Formula C22H22F3N
CAS Registry Number 226256-56-0
SMILES CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatic cancer09.04.02.008; 16.07.02.004--Not Available
Body temperature abnormal13.15.01.0300.007167%Not Available
Multiple organ dysfunction syndrome08.01.03.057--
Anal incontinence07.01.06.029; 17.05.01.021--
Blood parathyroid hormone abnormal13.10.07.0040.116458%Not Available
Blood parathyroid hormone decreased13.10.07.0010.092271%Not Available
Burn oesophageal07.11.02.004; 12.05.04.0050.001792%Not Available
Coeliac disease07.17.01.008; 10.04.04.012; 14.02.01.007--Not Available
Colonoscopy13.05.05.0040.001792%Not Available
Full blood count decreased13.01.07.004--Not Available
Hyperparathyroidism tertiary05.04.01.0060.001792%Not Available
Obstruction gastric07.13.04.0020.001792%
Recurrent cancer16.16.01.015--Not Available
Crystal deposit intestine13.05.03.0020.001792%Not Available
Spinal cord infection11.01.03.013; 17.06.02.0040.001792%Not Available
Laziness19.04.04.0050.002688%Not Available
Clostridium difficile infection11.02.02.009--Not Available
Gastric infection07.19.03.003; 11.01.07.0080.002688%Not Available
General physical condition abnormal13.15.01.0400.004479%Not Available
Hungry bone syndrome05.04.03.004; 14.04.04.014; 15.02.03.0150.001792%Not Available
Low turnover osteopathy14.04.04.015; 15.02.03.016; 20.01.01.010--Not Available
Heart valve incompetence02.07.02.0030.003583%Not Available
Bone density abnormal13.16.01.0050.001792%Not Available
Unevaluable investigation13.18.01.0140.035833%Not Available
Infected fistula08.01.03.072; 11.01.08.056; 15.03.02.0180.000701%Not Available
Internal haemorrhage24.07.01.0720.006271%Not Available
Thyroid hormones decreased13.10.06.0170.001792%Not Available
End stage renal disease20.01.03.0190.003583%Not Available
The 17th Page    First    Pre   17    Total 17 Pages